Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes

0 Views

07/07/23

In this 16-minute Platinum Lecture, Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut, discusses inroads into improved outcomes in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Petrylak emphasizes that all patients must be molecularly profiled (tested for MSI, mutational burden, and DNA damage response [DDR] mutations), explains checkpoint inhibition therapy is an appropriate treatment for those with MSI, and that PARP inhibition is appropriate for patients with DNA repair mutations.